Market revenue in 2023 | USD 18.6 million |
Market revenue in 2030 | USD 50.1 million |
Growth rate | 15.2% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.22% in 2023. Horizon Databook has segmented the Mexico head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
In Mexico, early diagnosis is vital, and healthcare providers encourage regular checkups and screenings, especially for individuals with risk factors associated with head and neck cancer. Timely and accurate diagnostics are essential for improving outcomes & tailoring appropriate treatment plans for head and neck cancer patients.
However, a lack of awareness about novel cancer screening methods in the country may restrict market growth. The Mexican government is trying to develop new policies to improve people's health. These include expanding public healthcare institutions' coverage along with standardizing the services offered by all of them.
The government is also implementing new programs for preventing cancer and other related diseases. The high prevalence of head and neck cancer in the country is the major driving factor. The below table represents the number of new head and neck cancer cases in Mexico.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account